Emergent Biosolutions Stock Price - EBS

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
After Hours
Last Trade
Last $ 54.43 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Emergent Biosolutions Inc EBS NYSE Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.32 0.59% 54.43 54.50 53.73 53.76 54.11 17:14:41
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,989 414,199 $ 54.10 $ 22,407,122 276,336 39.11 - 73.89
Last Trade Time Type Quantity Stock Price Currency
16:38:55 formt 11,239 $ 54.43 USD

Emergent Biosolutions Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.81B 51.62M $ 62.70M 1.22 767.90 49.23M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
2.31M $ - 0.00% - -

more financials information »

Emergent Biosolutions News

Loading Messages....

Latest EBS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EBS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week54.7556.0153.4054.46262,478-0.32-0.58%
1 Month54.3261.7752.2755.77288,2910.110.2%
3 Months40.4561.7740.1553.27420,42913.9834.56%
6 Months43.6261.7739.1148.86383,94010.8124.78%
1 Year69.0073.8939.1152.61425,616-14.57-21.12%
3 Years29.4673.8925.9647.15335,75324.9784.76%
5 Years23.8573.8923.6941.16341,95630.58128.22%

Emergent Biosolutions Description

Emergent BioSolutions Inc is a global biotechnology company that offers biopharmaceutical products to healthcare providers and governments. The company has two operating divisions: biodefense and biosciences. Its specialty biodefense division focuses on countermeasures that address public health threats. The U.S. government is the primary purchaser of these products and often provides substantial funding for their development. Emergent's biosciences business is primarily focused on hematology and oncology therapeutics, with a secondary focus on transplantation, infectious disease, and autoimmunity.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.